The Effect of Midazolam Premedication on Copeptine Concentration in Blood

Copeptin Clinical Trial

Official title:

The Effect of Midazolam Premedication on Copeptine Concentration in Blood

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03474939
• Other study ID #: MIDPRECOP
• Status: Completed
• Phase: Phase 4
• Start date: April 3, 2017
• Est. completion date: March 1, 2019

Study information

• Verified date: April 2019
• Source: Medical University of Warsaw
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aim is to assess whether premedication with midazolam prior to surgery affects copeptin concentration in blood.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 1, 2019
• Est. primary completion date: March 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients scheduled for elective surgery

• Patients with no chronic illness and considered ASA 1 by anesthesiologist

• Patients with mild and controlled chronic illness considered ASA 2 by anesthesiologist

Exclusion Criteria:

• Patient refusal

• Chronic illness requiring intense treatment or uncontrolled illness (ASA 3 or more)

Related Conditions & MeSH terms

• Copeptin
• Preanesthetic Medication

Intervention

Drug:
• Midazolam Oral Tablet
Midazolam Oral tablet

Other:
• Placebo Oral Tablet
Glucose 1000mg tablet night before surgery and 60 minutes before surgery

Locations

Country	Name	City	State
Poland	I Department of Anesthesiology and Intensive Care Medical University of Warsaw	Warsaw	Mazowieckie

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in copeptin concentration	Change in the concentration of copeptine measured in blood serum	48 hours